Bugworks, Cytecare collaborate for immuno-onco therapies

Indian startup Bugworks Research and Cytecare Cancer Hospitals, also in India, have announced first-of-its-kind collaboration. Bugworks develops best-in-class, novel therapies for cancer and infectious diseases and has set up a dedicated research centre within Cytecare, which is committed to excellence in treating cancer patients. Bugworks’ current research in immuno-oncology centres around modulating the tumour microenvironment that includes adenosine antagonism - an area of research with applications across many solid tumours. The drug candidates from this research will undergo translational testing on patient-derived tumours in the ex vivo laboratories at Cytecare, before progressing to first-in-human clinical studies. The outcome of this translational research will guide the first-in-human trials, expected to commence in early 2024.